Archives

  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • Deyo RA Cherkin DC Ciol MA Adapting a clinical

    2020-08-18

    [13] Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45(6):613e9. [14] Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol Dec 2000;53(12):1258e67. [15] Kang JH, Keller JJ, Lin HC. Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study. a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA Osteoporos Int Jan 2013;24(1): 271e7.
    [16] Herrera L, Leal I, Lapi F, et al. Risk of atrial fibrillation among bisphosphonate users: a multicenter, population-based, Italian study. a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA Osteoporos Int May 
    [17] Sharma A, Chatterjee S, Arbab-Zadeh A, et al. Risk of serious atrial fibrillation and stroke with use of bisphosphonates: evidence from a meta-analysis. Chest Oct 2013;144(4):1311e22.
    [20] Russell RGG, Rogers MJ, Frith JC, et al. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res 1999;14(S2):53e65.
    [21] Luckman SP, Hughes DE, Coxon FP, Russell RGG, Rogers MJ. Nitrogen-con-taining bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998;13(4):581e9.
    [22] Adami S, Braga V, Guidi G, Gatti D, Gerardi D, Fracassi E. Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. J Bone Miner Res 2000;15(3):599e604.
    [23] Montagnani A, Gonnelli S, Cepollaro C, et al. Changes in serum HDL and LDL cholesterol in patients with Paget’s bone disease treated with pamidronate. Bone 2003;32(1):15e9. [24] Ariyoshi T, Eishi K, Sakamoto I, Matsukuma S, Odate T. Effect of etidronic 125-04-2 on arterial calcification in dialysis patients. Clin Drug Investig 2006;26(4): 215e22.
    [25] Price PA, Faus SA, Williamson MK. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 2001;21(5):817e24. [26] O’Neill W. Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. 2009. [27] Price P, Roublick A, Williamson M. Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate. Kidney Int 2006;70(9):1577e83. [28] Elmariah S, Delaney JA, O’Brien KD, et al. Bisphosphonate use and prevalence of valvular and vascular calcification in women: MESA (The Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2010;56(21):1752e9. [29] Nitta K, Akiba T, Suzuki K, et al. Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term he-modialysis. Am J Kidney Dis 2004;44(4):680e8. [30] Cremers S, Papapoulos S. Pharmacology of bisphosphonates. Bone 2011;49(1): 42e9.
    [31] Omoigui S. The Interleukin-6 inflammation pathway from cholesterol to agingeRole of statins, bisphosphonates and plant polyphenols in aging and age-related diseases. Immun Ageing 2007;4(1):1.
    [35] Rossini M, Adami S, Viapiana O, et al. Circulating gammadelta T cellsand the risk of acute-phase response after zoledronic acidadministration. J Bone Miner Res 2012;27(1):227e30. [36] Rossini M, Adami S, Viapiana O, et al. Long-term effects of amino-bisphosphonates on circulating gammadelta T cells. Calcif Tissue Int 2012;91(6):395e9.
    [37] Giollo Alessandro, Rossini Maurizio, Gatti Davide, Adami Giovanni, Orsolini Giovanni, Angelo Fassio, Caimmi Cristian, Luca Idolazzi, Viapiana Ombretta. Amino-bisphosphonates and cardiovascular risk: a new hypothesis involving the effects on gamma-delta T cells. J Bone Miner Res 2019;34(570e571). 3.
    Contents lists available at ScienceDirect
    Biosensors and Bioelectronics
    journal homepage: www.elsevier.com/locate/bios
    Black phosphorus based fiber optic biosensor for ultrasensitive cancer T
    diagnosis
    Lin Zhoua,b, Chen Liua, Zhengbo Sunc, Hongju Maob, Lin Zhangd, Xuefeng Yuc, Jianlong Zhaob, Xianfeng Chena,∗ a School of Computer Science and Electronic Engineering, Bangor University, Bangor, LL57 1UT, United Kingdom
    b State Key Laboratory of Transducer Technology, Shanghai Institute of Microsystem and Information Technology, Chinese Academy of Sciences, Shanghai, 200050, China
    c Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China
    d Aston Institute of Photonic Technologies, Aston University, Birmingham, B4 7ET, United Kingdom